Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic

Overview

Journal J Prim Care Community Health

Publisher Sage Publications

Specialty Health Services

Date 2024 Apr 11

PMID 38600789

Authors

Sarah Alexandra Marshall

Lachan E Siebenmorgen

Katherine Youngen

Tyrone Borders

Nickolas Zaller

Affiliations

Soon will be listed here.

Abstract

Background: The COVID-19 pandemic catalyzed a rapid shift in healthcare delivery towards telehealth services, impacting patient care, including opioid use disorder (OUD) treatment. Regulatory changes eliminated the in-person evaluation requirement for buprenorphine treatment, encouraging adoption of telehealth. This study focused on understanding experiences of primary care providers in predominantly rural areas who used telehealth for OUD treatment during the pandemic.

Methods: Semi-structured interviews were conducted with 22 primary care providers. Participants practiced in 13 rural and 9 urban counties in Kentucky and Arkansas. Data were analyzed using conventional content analysis.

Results: The pandemic significantly impacted healthcare delivery. While telehealth was integrated for behavioral health counseling, in-person visits remained crucial, especially for urine drug screenings. Telehealth experiences varied, with some facing technology issues, while others found it efficient. Telehealth proved valuable for behavioral health counseling and sustaining relationships with established patients. Patients with OUD faced unique challenges, including housing, internet, transportation, and counseling needs. Stigma surrounding OUD affected clinical relationships. Building strong patient-provider relationships emerged as a central theme, emphasizing the value of face-to-face interactions. Regarding buprenorphine training, most found waiver training helpful but lacked formal education.

Conclusion: This research offers vital guidance for improving OUD treatment services, especially in rural areas during crises like the COVID-19 pandemic. It highlights telehealth's value as a tool while acknowledging its limitations. The study underscores the significance of strong patient-provider relationships, the importance of reducing stigma, and the potential for training programs to elevate quality of care in OUD treatment.

References

Marshall S, Stewart M, Barham C, Ounpraseuth S, Curran G . Facilitators and barriers to providing affirming care for transgender patients in primary care practices in Arkansas. J Rural Health. 2022; 39(1):251-261. PMC: 9705606. DOI: 10.1111/jrh.12683. View

Jones C, Diallo M, Vythilingam M, Schier J, Eisenstat M, Compton W . Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic. Drug Alcohol Depend. 2021; 225:108783. PMC: 9186054. DOI: 10.1016/j.drugalcdep.2021.108783. View

Volkow N, Frieden T, Hyde P, Cha S . Medication-assisted therapies--tackling the opioid-overdose epidemic. N Engl J Med. 2014; 370(22):2063-6. DOI: 10.1056/NEJMp1402780. View

Hughes P, Verrastro G, Fusco C, Wilson C, Ostrach B . An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic. J Rural Health. 2021; 37(3):467-472. PMC: 8250742. DOI: 10.1111/jrh.12570. View

Hser Y, Mooney L, Baldwin L, Ober A, Marsch L, Sherman S . Care coordination between rural primary care and telemedicine to expand medication treatment for opioid use disorder: Results from a single-arm, multisite feasibility study. J Rural Health. 2023; 39(4):780-788. PMC: 10718290. DOI: 10.1111/jrh.12760. View

Xierali I, Nivet M . The Racial and Ethnic Composition and Distribution of Primary Care Physicians. J Health Care Poor Underserved. 2018; 29(1):556-570. PMC: 5871929. DOI: 10.1353/hpu.2018.0036. View

Barreto T, Jetty A, Eden A, Petterson S, Bazemore A, Peterson L . Distribution of Physician Specialties by Rurality. J Rural Health. 2020; 37(4):714-722. DOI: 10.1111/jrh.12548. View

Huskamp H, Riedel L, Uscher-Pines L, Busch A, Barnett M, Raja P . Initiating Opioid Use Disorder Medication via Telemedicine During COVID-19: Implications for Proposed Reforms to the Ryan Haight Act. J Gen Intern Med. 2021; 37(1):162-167. PMC: 8553288. DOI: 10.1007/s11606-021-07174-w. View

Jones C, Shoff C, Hodges K, Blanco C, Losby J, Ling S . Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2022; 79(10):981-992. PMC: 9434479. DOI: 10.1001/jamapsychiatry.2022.2284. View

10.

Rezaeiahari M, Fairman B . Impact of COVID-19 on the characteristics of opioid overdose deaths in Arkansas. Int J Drug Policy. 2022; 109:103836. PMC: 9376304. DOI: 10.1016/j.drugpo.2022.103836. View

11.

Wen H, Borders T, Cummings J . Trends In Buprenorphine Prescribing By Physician Specialty. Health Aff (Millwood). 2019; 38(1):24-28. DOI: 10.1377/hlthaff.2018.05145. View

12.

Caton L, Cheng H, Garneau H, Fisher T, Harris-Mills B, Hurley B . COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics. J Gen Intern Med. 2021; 36(4):998-1005. PMC: 7842998. DOI: 10.1007/s11606-020-06436-3. View

13.

Magnan S . Social Determinants of Health 201 for Health Care: Plan, Do, Study, Act. NAM Perspect. 2021; 2021. PMC: 8406598. DOI: 10.31478/202106c. View

14.

Becker W, Fiellin D . When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis. Ann Intern Med. 2020; 173(1):59-60. PMC: 7138333. DOI: 10.7326/M20-1210. View

15.

Hsieh H, Shannon S . Three approaches to qualitative content analysis. Qual Health Res. 2005; 15(9):1277-88. DOI: 10.1177/1049732305276687. View

16.

Wilson C, Ramage M, Fagan E . A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder. J Rural Health. 2020; 37(1):169-171. PMC: 7262246. DOI: 10.1111/jrh.12438. View

17.

Kvamme E, Catlin M, Banta-Green C, Roll J, Rosenblatt R . Who prescribes buprenorphine for rural patients? The impact of specialty, location and practice type in Washington State. J Subst Abuse Treat. 2012; 44(3):355-60. PMC: 3886338. DOI: 10.1016/j.jsat.2012.07.006. View

18.

Sung M, Black A, Blevins D, Henry B, Cates-Wessel K, Dawes M . Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers. J Addict Med. 2022; 16(5):505-513. PMC: 9271533. DOI: 10.1097/ADM.0000000000000948. View

19.

Larochelle M, Jones C, Zhang K . Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021. Drug Alcohol Depend. 2023; 248:109933. DOI: 10.1016/j.drugalcdep.2023.109933. View

20.

Lott A, Danner A, Malte C, Williams E, Gordon A, Halvorson M . Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation. J Addict Med. 2023; 17(4):e262-e268. PMC: 10417321. DOI: 10.1097/ADM.0000000000001156. View